As Na­tion­al Par­ty Con­gress con­cludes, Chi­na’s FDA seeks to write wide­ly-an­tic­i­pat­ed drug re­forms in­to law

In a bid to move Chi­nese drug in­dus­try reg­u­la­tions clos­er to the US/Eu­ro­pean mod­el, Chi­na’s FDA yes­ter­day pro­posed sig­nif­i­cant changes to the na­tion’s Drug Ad­min­is­tra­tion Act.

The wide­ly ex­pect­ed move comes on the heels of in­struc­tions giv­en two weeks ago by the reign­ing State Coun­cil, Chi­na’s cab­i­net, just pri­or to the 19th Com­mu­nist Par­ty Con­gress meet­ing this past week. It con­firmed Xi Jing­ping as the most pow­er­ful Chi­nese leader since Mao and Deng, en­shrin­ing his per­son­al brand of so­cial­ism “with Chi­nese char­ac­ter­is­tics for a new era” in­to of­fi­cial dog­ma.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN